Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...

The S&P 500 has performed well in 2023, but healthcare stocks have lagged behind. Abbott Laboratories continues to lap difficult comparable quarterly earnings reports, but the core business has been ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

A new automation system from Abbott, designed to improve workflows in clinical lab settings, has been granted FDA approval. The system, GLP systems Track, uses a self-propelled carrier system that ...

Abbott Laboratories (NYSE:ABT) will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...

Abbott Diabetes Care said it had received reports of more than 700 injuries that may be associated with malfunctioning sensors. By Amanda Holpuch ByHeart, the maker of the product, has been linked to ...

On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...

A concussion test that Abbott Labs hopes someday could be used by sports team trainers and at urgent care clinics is now available for rapid use at the bedside, without having to send a sample to a ...

Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call Transcript October 15, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.3 EPS, expectations were $1.3.

Abbott Laboratories (NYSE: ABT) is a diversified health care company that gives investors a great deal of stability. Between testing, nutritional products, pharmaceuticals, and medical devices, the ...